Key result
Adjunctive letrozole prevents 12-month tumor recurrence in incompletely resected intravenous lipoleiomyoma with cardiac extension.
Why the study?
Intravascular lipoleiomyomas with cardiac involvement are rare and challenging to manage, especially when complete surgical resection is unachievable and recurrence occurs.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Adjunctive aromatase inhibitor therapy (such as letrozole) combined with surgical debulking provides a viable management strategy for hormone receptor-positive intravascular lipoleiomyomas with cardiac involvement when complete resection is unachievable.
BACKROUND: Lipoleiomyomas are rare, benign tumors combining smooth muscle and adipose tissue, most commonly found in the uterus. CASE SUMMARY: A 61-year-old woman with a history of surgical treatment of uterine leiomyoma presented with syncopal episodes. Echocardiography revealed masses in the right atrium that led to urgent partial resection of a 10-cm tumor originating from the iliac veins. Three years later, recurrence was detected, extending from the iliac vessels to the atrium. This required complex thoracoabdominal surgery with an R1/2 resection, indicating a high likelihood of tumor recurrence. Pathologic examination confirmed an angioleiomyomatous tumor. Given its hormone receptor positivity, adjunctive letrozole therapy was initiated. Follow-up scans showed tumor regression, and the patient remains asymptomatic. DISCUSSION: For hormone receptor-positive cases, aromatase inhibitors may offer a viable option for managing recurrent tumors when complete resection is unachievable. TAKE-HOME MESSAGE: This case underscores the importance of a multidisciplinary approach for intravenous leiomyomas with cardiac involvement.
No takes yet. Share an insight, caveat, or question.
Traub et al. (2025) conducted a case report in Intravascular Lipoleiomyoma (n=1). Surgical resection and adjunctive letrozole therapy was evaluated on Tumor recurrence or progression. In a patient with an incompletely resected, hormone receptor-positive intravenous lipoleiomyoma with cardiac extension, adjunctive letrozole therapy prevented tumor recurrence at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: